Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

World Health Organisation (WHO) has identified the new COVID variant, NB.1.8.1, detected in January, as a descendant of ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

As society becomes more relaxed about the perceived threat of Covid-19, the coronavirus has started to resurge in many ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...